Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study
Treatment with patiromer was effective in lowering and maintaining target sK levels, also well tolerated for one year in Japanese patients with hyperkalemia.
Authors
- Yasuro Kumeda
- Naoki Kashihara (ORCID: https://orcid.org/0000-0002-9487-984X)
- Yukio Tomioka
- Yoshitaka Maeda (ORCID: https://orcid.org/0000-0001-9729-687X)
- Takayuki Ishii (ORCID: https://orcid.org/0000-0002-1494-2141)
- Yuko Taniguchi
- Hidetoshi Kanai
- Yoko Kaneko
- Yorihiko Higashino
Institutions
- Kawasaki Medical School (JP)
- JA Toride Medical Center (JP)
- Higashi Takarazuka Satoh Hospital (JP)
- Osaka Hospital (JP)
- Zeria Pharmaceutical (Japan) (JP)
- Kokura Memorial Hospital (JP)
Publication Details
- Journal
- Clinical and Experimental Nephrology
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1007/s10157-024-02585-5
- Citations
- 2
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- AstraZeneca
- Baxter International
- Gilead Sciences
- Takeda Pharmaceutical Company
- GlaxoSmithKline Japan
- Boehringer Ingelheim Japan
- Daiichi-Sankyo
- Astellas Pharma
- Otsuka Pharmaceutical
- Toray Industries
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Bayer Yakuhin